With mid-stage trial failure, Rigel pares focus to two drugs
October 24, 2013 at 14:44 PM EDT
It's one drug down, two more to go for Rigel Pharmaceuticals Inc. The South San Francisco-based drug developer (NASDAQ: RIGL) said Thursday that its experimental treatment for lupus patients with skin lesions failed a Phase II study — the company's third piece of bad news over the past 10 months...
